tiprankstipranks
Trending News
More News >
TNL Mediagene (TNMG)
NASDAQ:TNMG
US Market
Advertisement

TNL Mediagene (TNMG) AI Stock Analysis

Compare
40 Followers

Top Page

TNMG

TNL Mediagene

(NASDAQ:TNMG)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
$0.50
▲(47.06% Upside)
TNL Mediagene's overall stock score is primarily impacted by its poor financial performance, characterized by significant profitability and cash flow challenges. Technical analysis indicates a bearish trend, further weighing down the score. The negative valuation metrics, including a negative P/E ratio and lack of dividend yield, also contribute to the low score. The absence of earnings call data and corporate events means these factors do not influence the overall score.
Positive Factors
Revenue Growth
Strong revenue growth indicates successful market expansion and product adoption, providing a solid foundation for future profitability.
Strategic Expansion
Expanding into new language markets can increase audience reach and revenue potential, supporting long-term growth and diversification.
Digital Asset Strategy
The digital asset strategy enhances financial flexibility and opens new business opportunities, aligning with industry trends and innovation.
Negative Factors
Profitability Challenges
Severe profitability issues indicate operational inefficiencies, posing risks to sustainable growth and financial stability.
Cash Flow Issues
Negative cash flow highlights liquidity concerns, limiting the company's ability to invest in growth and manage financial obligations.
High Leverage
High leverage increases financial risk, potentially limiting strategic flexibility and increasing vulnerability to economic downturns.

TNL Mediagene (TNMG) vs. SPDR S&P 500 ETF (SPY)

TNL Mediagene Business Overview & Revenue Model

Company DescriptionTNL Mediagene (TNMG) is a leading media and technology company specializing in the development and distribution of innovative digital content and solutions across various sectors, including healthcare, education, and entertainment. The company leverages cutting-edge technology to create engaging platforms and services that cater to a diverse audience, focusing on enhancing user experience and delivering high-quality, relevant content.
How the Company Makes MoneyTNMG generates revenue through multiple streams, primarily by offering subscription-based services, licensing agreements for its proprietary content, and advertising partnerships. The company has established significant collaborations with healthcare providers and educational institutions, providing tailored content solutions that meet specific sector needs. Additionally, TNMG monetizes its digital platforms through targeted advertising, leveraging user data analytics to optimize ad placements and maximize revenue potential.

TNL Mediagene Financial Statement Overview

Summary
TNL Mediagene is facing significant financial challenges. Despite a 35.3% revenue increase in 2024, the company suffers from severe profitability issues with a negative EBIT margin of -157.4% and a net profit margin of -175.3%. The balance sheet shows high leverage with a debt-to-equity ratio of 63.6%, and cash flow is negative, indicating liquidity concerns and operational inefficiencies.
Income Statement
20
Very Negative
TNL Mediagene's income statement reveals significant challenges. The company has experienced a rapid increase in total revenue year-over-year, with a notable increase of 35.3% in 2024 compared to 2023. However, this growth is overshadowed by substantial losses, exemplified by a negative EBIT margin of -157.4% and a net profit margin of -175.3% for 2024. The company faces profitability issues, which are further highlighted by negative EBITDA and net income, indicating operational inefficiencies and potential risks in sustaining growth.
Balance Sheet
30
Negative
The balance sheet of TNL Mediagene highlights a mixed financial position. While the company has managed to maintain a positive stockholders' equity in 2024, the debt-to-equity ratio is concerning at 63.6%, suggesting high leverage. The equity ratio stands at 39.2%, indicating moderate reliance on equity financing. However, the return on equity is negative due to consistent net losses, raising concerns about the company's ability to generate returns for shareholders.
Cash Flow
15
Very Negative
TNL Mediagene's cash flow statement underscores substantial cash management issues. The operating cash flow is negative, reflecting challenges in generating sufficient cash from operations. The company has a negative free cash flow growth rate, exacerbating liquidity concerns. Additionally, the free cash flow to net income ratio is unfavorable, indicating that the company struggles to convert its net income into positive cash flow, raising red flags about its financial health.
BreakdownDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue48.49M35.84M20.01M
Gross Profit17.74M12.65M7.74M
EBITDA-73.92M1.33M-10.01M
Net Income-85.00M-804.98K-11.01M
Balance Sheet
Total Assets92.92M119.62M26.53M
Cash, Cash Equivalents and Short-Term Investments3.65M3.03M3.91M
Total Debt23.14M17.59M6.71M
Total Liabilities56.51M47.25M50.67M
Stockholders Equity36.40M72.62M-25.30M
Cash Flow
Free Cash Flow-10.30M-1.68M-1.04M
Operating Cash Flow-10.21M-1.42M-760.11K
Investing Cash Flow947.95K252.74K-2.36M
Financing Cash Flow10.00M530.97K4.99M

TNL Mediagene Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.34
Price Trends
50DMA
0.35
Negative
100DMA
0.42
Negative
200DMA
0.86
Negative
Market Momentum
MACD
>-0.01
Positive
RSI
49.40
Neutral
STOCH
39.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNMG, the sentiment is Neutral. The current price of 0.34 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.35, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 49.40 is Neutral, neither overbought nor oversold. The STOCH value of 39.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TNMG.

TNL Mediagene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$7.86B-0.30-43.30%2.27%22.53%-2.21%
$922.09K-57.40%6.77%97.28%
$3.92M-0.10-60.37%-100.00%86.75%
$9.18M-164.27%4.59%-920.35%
$4.09M-0.08-660.37%74.27%
$4.19M-0.06-96.69%98.25%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TNMG
TNL Mediagene
0.34
-15.22
-97.81%
BDRX
Biodexa Pharmaceuticals
6.33
-50.47
-88.86%
SLRX
Salarius Pharmaceuticals
3.89
-17.86
-82.11%
LGMK
LogicMark
1.20
-1,742.55
-99.93%
BJDX
Bluejay Diagnostics
1.97
-1.67
-45.88%
STSS
Sharps Technology, Inc.
4.41
-883.59
-99.50%

TNL Mediagene Corporate Events

TNL Mediagene Plans Strategic Share Capital Increase Ahead of AGM
Oct 28, 2025

TNL Mediagene announced its upcoming Annual General Meeting of Shareholders, scheduled for November 25, 2025, where key proposals will be voted on, including a significant increase in authorized share capital from $50,000 to $500,000. This increase aims to provide flexibility for future capital raising and corporate purposes, supporting the company’s M&A roll-up strategy and digital asset treasury initiatives. The adoption of an Amended and Restated Memorandum and Articles of Association is also proposed to modernize the company’s constitutional documents, reflecting current laws and market practices.

TNL Mediagene Reports Strong H1 2025 Financial Results and Strategic Expansion
Oct 8, 2025

On October 7, 2025, TNL Mediagene announced its unaudited financial results for the first half of fiscal year 2025, showing a 5.7% increase in revenue to $21.8 million compared to the same period in 2024. The company improved its operating margin and reduced its net loss by 27.2%. TNL Mediagene has also reduced its outstanding debt by $5 million and is focusing on expanding its media properties into new language markets, enhancing AI-driven performance initiatives, and strengthening its leadership team. The company is committed to enhancing its capital markets presence and pursuing strategic partnerships to drive growth.

TNL Mediagene Unveils Digital Asset Treasury Strategy
Sep 18, 2025

TNL Mediagene announced on September 18, 2025, a strategic initiative to integrate digital assets into its business model by establishing a digital asset treasury (DAT), focusing on BTC, ETH, and SOL. This move aims to enhance financial flexibility and open new business opportunities in the digital asset space, complementing its existing media, technology, and digital studio operations. The company has formed a DAT advisory group with experts from leading digital asset and Web3 companies to guide the strategy’s development and ensure compliance with industry best practices. The DAT Strategy is expected to provide both financial and strategic benefits, supporting future growth initiatives and expanding the company’s media and data analytics platforms into the digital asset sector.

TNL Mediagene Amends Share Purchase Agreement with Tumim Stone Capital
Sep 16, 2025

On September 14, 2025, TNL Mediagene, a company incorporated in the Cayman Islands, entered into a third amendment to its ordinary share purchase agreement with Tumim Stone Capital LLC. This amendment allows TNL Mediagene to choose a pricing valuation period for its ordinary shares of either one or three trading days, impacting the maximum purchase amount and purchase price. This strategic move is expected to provide TNL Mediagene with greater flexibility in managing its equity line of credit, potentially enhancing its financial operations and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 24, 2025